Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and ...

Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial ...